Clinical trials: GFAP
Multiple Sclerosis
OFSEP Very High Definition Cohort
Multiple sclerosis (MS) is the most common acquired neurological disease leading to disability in young adults. MS often leads to the development of a physical and/or cognitive impairment that disables patients in their daily…
- Trial name
- VHD cohort (NCT05622643)
- Testing
- MRI
- Where
- 5 sites in France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- EDMUS Foundation
Kidney Transplant; Complications, Neurologic Manifestations
Evaluation of s100β, NSE and GFAP Levels in Renal Transplantation
Uremic encephalopathy is an organic brain disorder may be frequently seen in patients with acute or chronic renal failure. Certain neurological symptoms can be found under clinical glomerular filtration rate of 15 ml/minutes.
- Conditions
- Kidney Transplant; Complications, Neurologic Manifestations, Uremic Encephalopathy
- Trial name
- NCT04042272
- Testing
- S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Akdeniz University
Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder, Dementia, Neurodegenerative Disease
- Trial name
- DIV-AD (NCT07521722)
- Where
- Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Carotid Artery Stenosis, Carotid Artery Stenosis Asymptomatic
The VANGAS-Trial. The Value of Neurofilament Light Chain and Glial Fibrillary Acid Protein in the Blood of Patients With Asymptomatic Carotid Artery Stenosis
Stroke is the second leading cause of death and the third leading cause of disability worldwide. The cause is usually either a blockage or a severe narrowing of a cerebral artery.
- Conditions
- Carotid Artery Stenosis, Carotid Artery Stenosis Asymptomatic, Carotid Artery Diseases, Carotid Artery Plaque
- Trial name
- VANGAS (NCT06211725)
- Where
- 2 sites in Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Cognitive Dysfunction, Alzheimer Disease
Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults
BACKGROUND Cognitive decline in older adults, especially those who develop Mild Cognitive Impairment and Alzheimer's Disease, currently has limited options of pharmacological treatments, with modest efficacy.
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- NCT06733714
- Testing
- Transcranial Alternating Current Stimulation, Digital Cognitive Training
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio de Janeiro
Stroke, Stroke (CVA) or TIA
The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)
Stroke is a major cause of death and disability worldwide, frequently resulting in persistent cognitive deficits among survivors.
- Conditions
- Stroke, Stroke (CVA) or TIA, Dementia, Vascular, Cerebrovascular Disorders
- Trial name
- IC3 (NCT05885295)
- Testing
- MRI brain, Blood tests, cognitive assessments
- Where
- United Kingdom
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Anorexia Nervosa, Anorexia Nervosa Restricting Type
Novel Targetable BIOmarkers in ANorexia NervosA
The overall aim of this present study is to evaluate Growth Differentiation Factor-15 (GDF-15) and inflammatory cytokines as a possible novel and readily treatable target for the successful therapy of Anorexia Nervosa (AN).
- Trial name
- BIOANNA (NCT05885724)
- Where
- Switzerland
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
ALS - Amyotrophic Lateral Sclerosis
Comprehensive Biomarker Profiling of the IFN-α Pathway in Amyotrophic Lateral Sclerosis Patient Biofluids
ALS is characterized by significant genetic, clinical, and biological heterogeneity. The heritability of ALS is approximately 50%, and variants in more than 200 genes have been associated with the disease.
- Trial name
- NCT07260981
- Where
- Ireland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ulysses Neuroscience LTD
Donor Site Complication, Delirium
s100β, NSE n GFAP in Living Donor Hepatectomy and Delirium
The post-operative delirium picture is a serious and common complication seen after any major surgery, including hepatic resection.
- Conditions
- Donor Site Complication, Delirium, Uremic Encephalopathy, Neurologic Manifestations
- Trial name
- NCT04422925
- Testing
- Living Donor Hepatectomy
- Where
- Turkey (Türkiye)
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Akdeniz University
Neurofilament Light Chain, Glial Fibrillary Acidic Protein
Analysis of NfL and GFAP in Different Dietary Patterns
This observational study aims to investigate the impact of different dietary patterns on brain tissue biomarkers in healthy young adults by measuring blood levels of NfL and GFAP.
- Conditions
- Neurofilament Light Chain, Glial Fibrillary Acidic Protein, GFAP, Vegan Diet
- Trial name
- NCT07312994
- Where
- Austria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Salzburger Landeskliniken
Fatigue in Multiple Sclerosis, Multiple Sclerosis
Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease
The study is focused on several independent quantifiable biomarkers (sNfL, sGFAP, mitochondrial activity, genetics and fatigue tests) to obtain more detailed information about MS and its progression.
- Conditions
- Fatigue in Multiple Sclerosis, Multiple Sclerosis, Neurofilaments Light Chains, GFAP
- Trial name
- MITOFATIGUE (NCT07025122)
- Where
- Slovakia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Martin
Dementia Disorders, Mild Cognitive Impairment (MCI)
Multimodal Biomarkers in Individual With Cognitive Impairment and Dementia
Memory problems can range from normal aging to mild cognitive impairment (MCI) to dementia. This study looks at three ways of measuring what is happening in the brain at each of these stages: a blood test (GFAP), a brain MRI…
- Trial name
- NCT07812480
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Brain Damage, Postoperative
Evaluation of Neuronal Damage in Patients Undergoing Robot-assisted Laparoscopic Radical Prostatectomy With Biomarkers
Robotic assisted laparoscopic surgery has become an alternative to open or laparoscopic technique in various surgical fields. Robot assisted laparoscopic surgery is preferred by surgeons and patients due to easy accessibility…
- Conditions
- Brain Damage, Postoperative, Surgery-Complications
- Trial name
- NCT05692804
- Testing
- Mini Mental State Examination(MMSE),Montreal Cognitive Assessment ( MoCA),S100B ( protein S100 subunit beta) ,GFAP ( glial fibrillary acidic protein ),NSE ( neuron-specific enolase )
- Where
- Turkey (Türkiye)
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Akdeniz University
Multiple Sclerosis
Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients
Serum neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) measured by single molecule array (SIMOA) are novel biomarkers of multiple sclerosis patients (MS) activity and progression.
- Trial name
- Nf-Ella Loca (NCT05352971)
- Testing
- Biomarker quantification
- Where
- 10 sites in France
- Volunteers
- 664 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
Idiopathic inflammatory disorders of the central nervous system include various disorders of which multiple sclerosis is the most common.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Controls, Multiple Sclerosis
- Trial name
- AMIS (NCT04201470)
- Testing
- Blood withdrawal, MRI, Neurologic / neuropsychologic tests - Patients
- Where
- France
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier